Lombard Medical Technologies Share Discussion Threads

[25october1969] 04/4/2014 07:08

My guess, knowing the way the markets work, is that the price rise over the last two days is due to "insiders" knowing that they have got the placing away at a good price. Next task is to make sure that price does not fall on listing so I hope they sold a good story to US investors

[stable] 02/4/2014 13:36

baa
re small individual you are correct, but too many are prepared to sit and do nothing. The info re the proposed ipo was out their somewhere but you had to ask the right people the right question.
Fear about nasdaq frighten most small holders and they decided to sell. That decision should have been made when the first announcement was made a month ago.
Like you many are holding. current maths are potentialy in our favour, but nothing is certain

[baa] 02/4/2014 13:10

So all the private punters who've sold in the last few weeks have just been mopped up by an institution , buying 70K at 165p = £115K. That'll be 17,500 new shares next week - at the lower end of the range , that's $262500 or say £159,000.

You have to laugh how the whole game is so biased away from the individual .

I'm holding mine and will see what happens post ipo.

[skinny] 01/4/2014 12:40

Unfortunately the $80m is from March 10th.

[25october1969] 01/4/2014 12:27

I'll see your $60m and raise you $20m

[shorewalk] 01/4/2014 12:12

www.nasdaq.com/article/stent-developer-lombard-medical-sets-terms-for-60-million-us-ipo-cm340161

[nod] 28/3/2014 04:56

All this effort to list on Nasdaq and we will get acquired within a year :)

[callumross] 12/3/2014 23:26

Ridiculously high the valuation of this company compared to the miniscule sales and losses. No market in the shares shortly either!

[munkychunky] 12/3/2014 13:01

yeah... but still higher than the next one ;)

[shorewalk] 12/3/2014 11:49

Ridiculous back to the level of the last fundraising.

[nod] 11/3/2014 11:03

Increase in Aorfix revenue of 1.1 million to 6.1 m. Not the growth I was hoping for but 0.5 million came from the USA.New ticker on Nasdaq of EVAR

[skinny] 11/3/2014 07:11

Operational highlights
· US FDA approval of Aorfix™ for the endovascular repair of AAAs in February 2013
o Only endovascular stent graft approved by the US for use in cases with neck angulation up to 90 degrees
· US FDA approval of Aorflex™, the next generation delivery system for Aorfix in June 2013
· Official US launch of Aorfix together with Aorflex at the VEITH Symposium in New York in November 2013
· Following US Aorfix approval, recruited and trained a US direct sales force of 20 individuals, including two regional managers
· Trained 244 physicians in the US to use Aorfix between July and December 2013
· Appointment of Raymond W. Cohen as Non-Executive Chairman in July 2013

Financial highlights
· Total revenue increased by 13% to $7.0m (2012: $6.2m)
· Aorfix commercial revenue increased 23% to $6.1m (2012: $5.0m)
o Aorfix revenue in main EU markets increased 8% to $3.9m (2012: $3.6m)
o Aorfix revenue in the US was $0.5m following launch in H2 2013
· Operating loss increased to $20.0m (2012: $13.1m) due to increases in sales and marketing headcount and activity in the US
· Cash and cash equivalents of $40.9m as at December 31, 2013 (December 31, 2012: $4.5m), increased primarily through the receipt of $53.2m (£34.4m) from equity fundraisings
· Financing:
o US approval of Aorfix in February 2013, which triggered receipt of the $20.4m (net of expenses) second tranche of the two tranche April 2011 fundraising
o US approval of Aorfix triggered Company's ability to draw down $2.5m from the $5.0m loan facility granted by our exclusive Japanese distribution partner, Medico's Hirata Inc.
o Raised an additional $32.8m (net of expenses) in June 2013 through a placing, subscription and offer for new shares

Post period events
· Live case demonstration using Aorfix at
o 2014 Leipzig Interventional Course (LINC) in Germany
o iCON 2014, a meeting of the International Society of Endovascular Specialists in Phoenix, Arizona
· Approval for Aorfix in Japan continues to be anticipated in 2014


This press release does not constitute an offer of any securities for sale. As a result of regulations applying to the Company after the filing of a Form F-1 Registration Statement with the US Securities and Exchange Commission on 10 March 2014, this press release does not include comments on Outlook or by our Chief Executive Officer.

-Ends-

[nod] 06/3/2014 21:35

I fully agree with all those posts today - it's not a level playing field and the PIs get shafted all the time. This is common across the LSE these days as all companies are using the same set of brokers with the same greedy mentality and disregard for PIs.I've been complaining about this on PTEC where a placing of 45 million shares (326 million quid) is limited to institutions and their mates and directors. Fortunately in many of these situations the share price tends to fall close to the listing price and often below it as many instis sell quickly to make a quick buck. So PIs will often get a chance to buy close to the issue price or maybe below it.In the case of LMT, I think the move to Nasdaq will be beneficial and greatly increase interest and liquidity in the shares. I'm happy to hold these as LMT is finally selling products and prospects look brighter than ever.I decided not to add as I thought the share price may become volatile ahead of the delisting on London and a lower price may be possible before d-day.

[munkychunky] 06/3/2014 17:27

Well at least they gave shareholders the option to participate in the last placing a year or so back.. But yeah, kinda feel the same, hence my sale. Don't mean the share won't do well in the US, but those that are able to subscribe to the IPO will do the best I think.

[stable] 06/3/2014 16:25

I have been in Lmt for years, and intend to keep current holdings, but, recent events have shown that company and house broker have no interest in small stock holder as they are forced to do what the big boys want to do
I am sure that all those large holders know so much more than we do and one of those details is the price that is going to be used when new money is raised in the US of A.
Also I believe the Japaneses news that was until recently expected 1 st quarter
this year has been delayed to suit LMT so that after we go to Nasdq there will be an announcement giving a boost to the shareprice and all those very lucky us holders.
The volume recently seen does not justify a 12.5 percent fall without some prior knowledge.
Perhaps I am letting my imagination grow but I will stay until something makes me feel differently, but it does not stop me feel that I have been taken over a barrell and been f.....d.

[munkychunky] 06/3/2014 13:27

The share price moves so much as the market for LMT is not very liquid. I am of the opinion that the IIs already invested would have had first refusal with regard to taking part in any placing - thats just my opinion - I don't know...

Since the announcement of the move to aim there had always been included in the news releases disclosure with regard to further financing, but the first time I've seen figures mentioned was in the publication of the circular.

[shorewalk] 06/3/2014 12:44

Your views on major shareholders corroborate mine. That also makes the price movement on such small trades so peculiar. Japan approval imminent? Agree about prospectus.

[shorewalk] 04/3/2014 22:21

So what if there is a dilution. What matters is the value the company achieves. If the fundraising means the company makes growth and profit sooner all shareholders benefit - or am I just naïve.

[munkychunky] 04/3/2014 16:16

Circular is out now on the website:

hxxp://www.lombardmedical.com/pwpcontrol.php?pwpID=17081

Unfortunately it looks like to me that existing holders can not participate in the fundraising which accompanies the change of listings. On that note. I've sold up here - Dilution expected to be 25-34% if I read it correctly...

GLA, I'm sure it'll be alright long term.

[skinny] 26/2/2014 11:31

It isn't there (yet).

[munkychunky] 26/2/2014 11:25

Anyone got a link to the circular yet? I could not see it on the website... just the RNS